Taisho Boosted By Overseas Sales With Japanese Business Flat
Executive Summary
Taisho's Self-Medication business posted a solid gain in the six months ended 30 September as a recovery in its Overseas operation boosted a flat performance in Japan.
You may also be interested in...
Taisho To Go Private To Aid 'Dynamic' Restructuring, R&D Investment
The largest shareholder in major Japanese pharma firm Taisho, the founding Uehara family, intends to smooth the way to the restructuring and expansion of the business by acquiring and delisting all of its stock. The nearly $5bn size of the deal would makes it the biggest management buyout in Japanese corporate history.
Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories
Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.